StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Stock Performance NASDAQ CYCC opened at $0.65 on Thursday. The stock’s fifty day moving average is $0.65 and its two-hundred day moving average […]
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews com kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
StockNews com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note released on Tuesday. The firm issued a sell rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Price Performance Shares of NASDAQ CYCC opened at $0.60 on Tuesday. The company’s 50-day simple moving average is $0.62 and its 200-day simple […]
StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research report released on Monday. The firm issued a sell rating on the biotechnology company’s stock. Separately, Oppenheimer lowered their target price on shares of Cyclacel Pharmaceuticals from $10.00 to $8.00 and set an outperform rating for the company in a […]